8-K: Scilex Holding Co. Announces $10 Million Public Offering of Common Stock and Warrants

Scilex Holding Company has entered into an agreement to sell 5,882,353 shares of common stock and accompanying warrants at $1.70 per share, aiming to raise approximately $10 million.

Summary

• Scilex Holding Company has announced a public offering to sell 5,882,353 shares of its common stock along with warrants to purchase an equal number of shares.
• The offering price is set at $1.70 per share and accompanying warrant, before accounting for underwriting discounts and commissions.
• The company expects to raise approximately $10 million in gross proceeds from this offering, assuming no exercise of the underwriter's over-allotment option.
• The underwriters have a 30-day option to purchase an additional 882,352 shares and/or warrants.
• The offering is expected to close around March 5, 2024, subject to customary closing conditions.
• The net proceeds from the offering will be used for working capital, general corporate purposes, potential acquisitions, and debt repayment.

Sentiment

Score: 6

Explanation: The announcement is a standard capital raise, which is generally neutral. The company is raising funds for growth, but the dilution of shares is a negative. The sentiment is therefore slightly positive.

Positives

• The capital raise will provide Scilex with additional funds for working capital and general corporate purposes.
• The offering allows Scilex to potentially fund acquisitions, research and development, and commercialization efforts.
• The company has the option to raise additional capital through the underwriter's over-allotment option.

Negatives

• The offering will dilute existing shareholders' ownership.
• The company is raising capital at a price of $1.70 per share, which may be perceived as low.
• The company is relying on the capital markets to fund its operations and growth.

Risks

• The closing of the offering is subject to customary closing conditions, which may not be met.
• The company's future performance is subject to various risks, including clinical trial outcomes, regulatory approvals, and market acceptance of its products.
• The company's forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially.

Future Outlook

The company intends to use the net proceeds from the offering for working capital, general corporate purposes, potential acquisitions, and debt repayment. Scilex also plans to launch Gloperba in 2024 and initiate a Phase 2 trial for SP-104 in 2024.

Management Comments

• Scilex has entered into an underwriting agreement with Rodman & Renshaw LLC and StockBlock Securities LLC for the public offering.

Industry Context

This capital raise is occurring in the context of Scilex's focus on developing and commercializing non-opioid pain management products, a growing area of interest in the pharmaceutical industry due to the opioid crisis. The company is seeking to expand its product portfolio and commercial reach.

Comparison to Industry Standards

• The offering size of $10 million is relatively small compared to larger pharmaceutical companies, but is typical for a company of Scilex's size and stage of development.
• The use of proceeds for working capital and general corporate purposes is standard for companies raising capital through public offerings.
• The inclusion of warrants in the offering is a common practice to attract investors, particularly in the biotech and pharmaceutical sectors.
• Comparable companies in the pain management space often raise capital through similar methods to fund clinical trials and commercialization efforts.

Stakeholder Impact

• Shareholders will experience dilution of their ownership due to the issuance of new shares.
• The company will have additional capital to fund its operations and growth, which could benefit stakeholders in the long term.
• The offering could potentially lead to increased market awareness and investor interest in Scilex.

Next Steps

• The company will proceed with the closing of the offering, expected on or about March 5, 2024.
• Scilex will use the net proceeds for working capital, general corporate purposes, and potential acquisitions.
• The company plans to launch Gloperba in 2024 and initiate a Phase 2 trial for SP-104 in 2024.

Key Dates

Keywords

public offering, common stock, warrants, capital raise, underwriting agreement, Scilex Holding Company, Rodman & Renshaw, StockBlock Securities, working capital, non-opioid pain management